Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Cellectis SA

CLLS
1,56
0,08 (5,41%)
Pre Mercato
Ultimo aggiornamento: 14:12:21
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/12/202422:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/12/202422:30GLOBECellectis announces the drawdown of the third tranche of €5..
05/11/202422:30GLOBECellectis Presents Multiple Strategies to Enhance CAR T-cell..
04/11/202422:30GLOBECellectis Provides Business Updates and Financial Results..
30/10/202421:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202421:30GLOBECellectis to Report Third Quarter 2024 Financial Results on..
22/10/202408:00GLOBECellectis to Present Data on TALE-Base Editors and Non-Viral..
11/9/202422:30EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
03/9/202422:30GLOBECellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells..
26/8/202422:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/8/202422:30GLOBECellectis Publishes a Molecular Therapy Article on a SMART..
07/8/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202408:00GLOBECellectis Appoints Dr. Adrian Kilcoyne as Chief Medical..
06/8/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/8/202422:30GLOBECellectis Provides Financial Results for the Second Quarter..
01/8/202422:30GLOBEFDA Grants Orphan Drug Designation to Cellectis’ CLLS52..
25/7/202422:30GLOBEFDA Grants Orphan Drug and Rare Pediatric Disease..
28/6/202422:30GLOBECellectis Reports Results from Shareholders Meeting Held on..
20/6/202422:30GLOBECellectis Publishes a Scientific Article Unveiling Three Key..
12/6/202422:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/6/202422:30GLOBECellectis Unveils a Non-Viral Gene Therapy Approach for..
04/6/202422:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/6/202422:30GLOBECellectis Receives Orphan Drug Designation for UCART22, its..
29/5/202422:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/5/202422:30GLOBECellectis’ Annual Shareholders General Meeting to be Held on..
28/5/202422:30GLOBECellectis Reports Financial Results for First Quarter 2024
28/5/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/5/202422:30GLOBECellectis to Report First Quarter 2024 Financial Results on..
24/5/202422:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202408:00GLOBECellectis Announces Completion of the Additional Equity..
02/5/202422:30GLOBECellectis Appoints Arthur Stril as Interim Chief Financial..
29/4/202422:46GLOBECellectis Reports Financial Results for the Fourth Quarter..
22/4/202422:30GLOBECellectis Presents Novel TALEN® Editing Processes Enabling..
10/4/202422:30GLOBECellectis Publishes a Novel Intronic Gene Editing Approach..
08/4/202422:30GLOBECellectis Announces Two Poster Presentations on Novel TALEN®..
Apertura: Min: Max:
Chiusura: 1,48

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network